Method for treatment of diseases of central nervous system (CNS) and improvement of cognitive function by nanoscaffolds
TS-038406 — A novel method to improve CNS metabolism and overall cognitive function as well as reduce peripheral neurodeneration, through the use of nanomatrices with or without identified redefined delivery biologicals and/or insulin.
The central nervous system (CNS) can be implicated in a broad category of diseases in which the brain does not function as expected. Conditions may result from a metabolic disorder; damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or…
The central nervous system (CNS) can be implicated in a broad category of diseases in which the brain does not function as expected. Conditions may result from a metabolic disorder; damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors (Intl. Neuromodulation Society). Disorders of the nervous system include Parkinson’s disease, multiple sclerosis, Alzheimer disease, epilepsy and Bell’s palsy among others. According to the most recent statistics from the United Nations, nearly 1 in 6 of the world’s population, up to 1 billion people, suffer from neurological disorders. The development of new pharmaceutical products has successfully addressed a multitude of disease states; however, new product development for treating disorders of the central nervous system (CNS) has lagged behind other therapeutic areas. This is due to several factors including the complexity of the diseases and the lack of technologies for delivery. As the global population continues to increase, there is a growing demand in both developing and developed countries for effective treatment of CNS disease and neurological disorders.
Researchers at The Ohio State University, led Dr. Ouliana Ziouzenkova and Dr Jonathan Parquette, have developed a method for producing nanomatrices that can be used to treat central nervous system disorders and promote cognitive function. This technology can improve CNS metabolism and overall cognitive function as well as reduce peripheral neurodeneration, with our without the addition of biologicals and/or insulin. These short synthetic peptides prepared from natural amino acids allow noncovalent binding of functional molecules and do not require degradation or release of the functional component to exhibit activity.
- Protection against neurodegeneration
- Appetite-reducing agent production
- Improvement of cognitive function
- Treatment of neurological conditions, including major depressive disorders
- Provides synthetic extracellular matrix capable of supporting neurons and cells of their environment
- Improves energy metabolism of CNS and peripheral nervous system resulting in reduced neurodegeneration
- Provide microenvironment enriched in nutrients that facilitating interaction with intestinal or epithelial cells controlling nutrient delivery to the brain
- Bind nutrients with and without proteins facilitating their adhesion or transport of nutrients into CNS or the desired tissue influencing CNS.